Chardan Capital raised their FY2025 earnings estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, February 19th. Chardan Capital analyst Y.

In a report released today, Gena Wang from Barclays maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price target ...

JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Solid Biosciences (SLDB – Research Report) today and set a price target of ...

$SLDB insiders have traded $SLDB stock on the open market 17 times in the past 6 months. Of those trades, 2 have been purchases and 15 have been sales. Here’s a ...

Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.

Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...

Solid Biosciences Inc. (NASDAQ:SLDB), a clinical-stage biotechnology company specializing in gene therapies for muscle and cardiac diseases, stands at a critical juncture as it approaches key ...

Shares of Solid Biosciences (NASDAQ:SLDB) jumped ~88% in the premarket on Tuesday after the gene therapy developer reported promising early results from a Phase 1/2 trial for its lead asset SGT ...